Key Takeaways
- Novo Nordisk intends to submit its oral Wegovy formulation for Chinese regulatory clearance “within a few months”
- New CEO Mike Doustdar announced the timeline during his inaugural China trip after assuming leadership in August
- Eli Lilly gained first-mover advantage by filing orforglipron with Chinese authorities in late 2025
- China’s semaglutide patent lapsed in March, opening doors for generic rivals from Q2 2026 onward
- NVO stock edges up 0.09% while analysts maintain a Hold rating with a $46 price target
Novo Nordisk is accelerating its entry into China’s burgeoning oral obesity treatment sector, with CEO Mike Doustdar announcing the pharmaceutical giant will seek regulatory clearance for its pill-based Wegovy formulation “very soon — a few months.”
Doustdar revealed the timeline while making his maiden voyage to China following his appointment to the chief executive position last August. At the time of his statement, NVO stock registered a modest 0.09% gain.
China represents the globe’s second-largest pharmaceutical marketplace, with GLP-1 weight-loss medications emerging as one of the most rapidly expanding drug segments. First-quarter sales of GLP-1 therapies through Alibaba and JD.com platforms alone reached approximately 1.4 billion yuan ($207 million), according to data from Jefferies.
Novo has already established a presence in the Chinese market. The company secured Chinese regulatory clearance for injectable Wegovy in mid-2024. A tablet formulation would provide the Danish drugmaker an additional competitive avenue, appealing to patients who favor oral medications over needle-based administration.
However, the company faces an uphill battle. Eli Lilly filed its once-daily oral medication orforglipron with Chinese regulatory bodies at year-end 2025, positioning itself ahead in the approval pipeline. Lilly has also commercialized Mounjaro throughout China for both Type 2 diabetes treatment and weight control.
Generic Competition Looms Large
The competitive landscape extends beyond Lilly. Semaglutide — the active pharmaceutical ingredient powering both Wegovy and Ozempic — forfeited patent exclusivity in China this past March. While Novo maintains regulatory data exclusivity through early next year, generic alternatives are projected to surface as soon as Q2 2026.
Doustdar recognized the emerging challenge but emphasized manufacturing complexity as a defensive moat. “Not many of our competitors will be able to reach that level, have the capabilities,” he stated, highlighting the sophisticated production requirements for oral formulations at commercial scale.
To maintain competitiveness against generic producers and domestic imitation products, Novo has implemented price reductions for Wegovy in select Chinese markets.
Pfizer and domestic pharmaceutical company Innovent Biologics have likewise entered the competitive arena, though comprehensive market-share data for China remains opaque. Neither Innovent nor Lilly provides granular Chinese revenue breakdowns.
Novo introduced its Wegovy tablet in U.S. markets earlier this calendar year after obtaining expedited approval domestically and in the UK. Lilly secured U.S. regulatory approval for orforglipron in April.
Wall Street Perspective
Among Wall Street analysts, NVO maintains a Hold consensus rating derived from three uniform Hold recommendations on TipRanks. The consensus price target stands at $46, suggesting approximately 4.7% appreciation potential from present trading levels.
Since the beginning of the year, NVO has declined 11.4%, mirroring investor apprehension surrounding patent vulnerability, pricing dynamics, and intensifying competitive pressures.
According to Doustdar, the China regulatory submission is anticipated within the coming months.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
